Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-08-30
2005-08-30
LeGuyader, John L. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S325000, C435S366000, C435S375000, C536S023100, C536S024310, C536S024330, C536S024500
Reexamination Certificate
active
06936593
ABSTRACT:
Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.
REFERENCES:
patent: 4309404 (1982-01-01), DeNeale et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4556552 (1985-12-01), Porter et al.
patent: 4704295 (1987-11-01), Porter et al.
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5220007 (1993-06-01), Pederson et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5271941 (1993-12-01), Cho-Chung
patent: 5403709 (1995-04-01), Agrawal et al.
patent: 5442049 (1995-08-01), Anderson et al.
patent: 5470967 (1995-11-01), Huie et al.
patent: 5510239 (1996-04-01), Baracchini et al.
patent: 5514577 (1996-05-01), Draper et al.
patent: 5578716 (1996-11-01), Szyf et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5612212 (1997-03-01), Gewirtz
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5969117 (1999-10-01), Agrawal
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 6645943 (2003-11-01), Agrawal et al.
patent: 2004/0033980 (2004-02-01), Agrawal et al.
patent: 92/03568 (1992-03-01), None
patent: 93/08296 (1993-04-01), None
patent: 93/13114 (1993-07-01), None
patent: 93/13740 (1993-07-01), None
patent: 93/19203 (1993-09-01), None
patent: WO 94/17093 (1994-01-01), None
patent: 94/02498 (1994-02-01), None
patent: 94/15619 (1994-07-01), None
patent: 94/19945 (1994-09-01), None
patent: WO94/23028 (1994-10-01), None
patent: WO96/12497 (1996-05-01), None
patent: WO97/11171 (1997-03-01), None
Agrawal; “In Vivo Pharmacokinetics of Oligonucleotides”; inApplied Antisense Oligonucleotide Technology(Stein and Krieg, Eds, Eds.), pp. 365-385 (1998).
Agrawal, “Preface”, inMethods in Molecular Medicine: Antisense Therapeutics(Agrawal, Ed.); pp. v-vii (1996).
Agrawal, et al.; “Comparative Pharmacokinetics of Antisense Oligonucleotides”; inMethods in Molecular Medicine; Antisense Therapeutics(Agrawal, Ed.); pp. 247-270 (1996).
Branch; “A Good Antisense Molecular is Hard to Find”; TIBS 23; pp. 45-50, Feb. 1998.
Crooke; “Basic Principles of Antisense Therapeutics”; inAntisense Research and Application(Crooke, Ed.); pp. 1-50 (1998).
Crystal; “Transfer of Genes to Humans: Early Lessons and Obstacles to Success”; Science; vol. 270, pp. 404-410 (1995).
Friedmann; “Overcoming the Obstacles”; Scientific American; pp. 96-101, Jun. 1997.
Monia, et al.; “Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase”; Nature Medicine; vol. 2, No. 6, pp. 668-675, Jun. 1996.
Schofield et al.; “Non-viral Approaches to Gene Therapy”; British Medical Bulletin; vol. 51, No. 1, pp. 56-71, (1995).
Verma, et al.; “Gene Therapy—Promises, Problems, and prospects”; Nature; vol. 389, pp. 239-242, Sep. 1997.
Vlassov, et al.; “In Vivo Pharmacokinetics of Oligonucleotides Following Administration by different Routes”; inDelivery Strategies for Antisense Oligonucleotide Therapeutics(Akhtar, Ed.); pp. 71-83 (1995).
Vlassov, et al.; “Penetration of Oligonucleotides into Mouse Organism through Mucosa and Skin”; FEBS Letters; vol. 327, No. 3, pp. 271-274; Aug. 1993.
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus”,Proc. Natl. Acad. Sci.USA, vol. 85, pp. 7079-7083 (1988).
Agrawal et al., “Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothiaote analogues”,Proc Natl Acad Sci U S A., vol. 86, pp. 7790-7794 (1989).
Agrawal et al., “Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides”,Proc Natl Acad Sci U S A., vol. 87, pp. 1401-1405 (1990).
Agrawal et al., “Pharmscokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice”,Proc Natl Acad Sci U S A., vol. 88, pp. 7595-7999 (1991).
Agrawal, “Antisense oligonucleotides as antiviral agents”,Trends in Biotechnol., vol. 10, pp. 152-158 (1992).
Agrawal, “Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups”,Methods in Molecular Bilology; Protocols for Oligonucleotides Conjugates(Agrawal, Ed.) Humana Press., pp. 93-120 (1994).
Agrawal, et al., “Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrtions in Experimental Animals”,Handbook of Experimental Pharmacology, vol. 131: Antisense Research and Application(Crooke, Ed.), Springer-Verlag, pp. 525-543 (1998).
Bayever et al., “Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial”,Antisense Res Dev.vol. 3, pp. 383-390 (1993).
Boutorine et al, “Effect of derivatization of ribophosphate backbone and terminal ribophosphate groups in oligoribonnucleotides on their stability and interaction with eukaryotic cells”,Biochimievol. 76, pp. 23-32 (1994).
Ceruzzi et al., “The intracellular and Extracellular Fate of Oligodeoxyribonucleotides in Tissue Culture Systems”,Nucleosides and Nucleotides8 (5&6), 815-8 (1989).
Craig et al., “Patent Strategies in the Antisense Oligonucleotides Based Therapeutic Approach”,Exp. Opin. Ther. Patents, vol. 7, No. 10, pp. 1175-1182 (1997).
Crooke, S. T., “Progress in the Development of Antisense Drugs”,Exp. Opin. Invest. Drugs, vol. 5, No. 8, pp. 1047-1052 (1996).
Egli et al., Structure Origins of the High RNA Affinity of 2′-O-Methyoxyethyl RNA: Crystal Structure of an All-Modified 2′-O-MOE RNA Dodecamer Duplex, Antisense 98: Targeting the Molecular Basis of Disease, oct. 8-9, 1998.
Furdon et al., “RNase H cleavage of RNA hybridized to Oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds”,Nucleic Acids Res., vol. 17, No. 22, pp. 9193-9204. (1989).
Rapaport et al., “Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistantPlasmodium falciparum”, Proc Natl Acad Sci U S A., vol. 89, pp. 8577-8580 (1992).
Sands, et al., “Biodistribution and metabolism of internally3H-labeled oligonucleotides. I. Comparsion of a phosphodiester and a phosphorothioate”,Mol. Pharmacol., vol. 45, pp. 932-943 (1994).
Shibahara et al., “Site-directed cleavage of RNA”,Nucleic Acids Res., vol. 15, No. 11, pp. 4403-4415 (1987).
Shibahara et al., “Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives,”Nucleic Acids Res., vol. 17, No. 1, pp. 239-252 (1989).
Sonveaux, “Protecting Groups in Oligonucleotide Synthesis”Methods in Molecular Biology: Protocols for Oligonucleotide Conjugates(Agrawal ed.), Humana Press, pp. 1-71 (1994).
Stein et al., “Antisense oligonucleotides as therapeutics agents—is the bullet really magical?”Science, vol. 261, pp. 1004-1012 (Aug. 1993).
Takashima et al., “tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity,”Proc Natl Acad Sci U S A., vol. 90, pp. 7789-7793 (1993).
Tidd et al., “Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups,”Br J Cancer
Agrawal Sudhir
Diasio Robert B.
Zhang Ruiwen
Gibbs Terra C.
Hybridon, Inc.
LeGuyader John L.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Method of down-regulating gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of down-regulating gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of down-regulating gene expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514175